Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Therapy for diastolic heart failure.

William C Little¹, Steffen Brucks

¹Department of Medicine, Cardiology Section, Wake Forest University School of Medicine Winston-Salem, NC, USA. wlittle@wfubmc.edu

Progress in Cardiovascular Diseases

|August 24, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Low-dose versus high-dose drug-coated balloons for femoropopliteal lesions: 5-year results from the prospective, randomised COMPARE trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026

Same author

Low-Dose vs High-Dose Paclitaxel-Coated Balloons for Femoropopliteal Lesions: 2-Year Results From the COMPARE Trial.

JACC. Cardiovascular interventions·2022

Same author

Long-Term Effectiveness and Safety of Femoropopliteal Drug-Coated Balloon Angioplasty : 5-Year Results of the Randomized Controlled EffPac Trial.

Cardiovascular and interventional radiology·2022

Same author

Assessment of 5-Year Mortality Outcomes for Femoropoliteal Interventions Using Drug-Eluting Devices in the REAL-PTX Study.

JACC. Cardiovascular interventions·2021

Same author

Drug-coated Balloon Angioplasty of Femoropopliteal Lesions Maintained Superior Efficacy over Conventional Balloon: 2-year Results of the Randomized EffPac Trial.

Radiology·2020

Same author

COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions.

European heart journal·2020

Diastolic heart failure therapy is guided by treating underlying conditions like hypertension. Proven systolic heart failure treatments may benefit diastolic patients, especially those with hypertension.

Area of Science:

Cardiology
Heart Failure Research

Background:

Diastolic heart failure lacks clear therapeutic guidelines.
Pathophysiology of diastolic and systolic heart failure share similarities.

Purpose of the Study:

To explore potential therapeutic benefits for diastolic heart failure.
To investigate the role of managing comorbidities in diastolic heart failure management.

Main Methods:

Review of existing literature on heart failure pathophysiology and treatment.
Analysis of the impact of managing comorbidities on diastolic heart failure outcomes.

Main Results:

Treating underlying conditions (hypertension, left ventricular hypertrophy, ischemia, diabetes, anemia, obesity, pulmonary disease) is crucial.

Related Experiment Videos

Systolic blood pressure control improves and prevents diastolic heart failure.

Treatment is most effective in hypertensive patients with diastolic heart failure.

Acute systolic blood pressure management reduces congestion and ischemia.

Chronic management may lead to left ventricular hypertrophy regression.

Conclusions:

Managing comorbidities is key for diastolic heart failure.
Hypertension control is particularly effective.
Patients without hypertension present significant treatment challenges.